Chiome Bioscience TSE:4583 Stok Raporu Chiome Bioscience Inc.
TSE:4583 Stok Raporu
4583 Stoklara Genel Bakış Chiome Bioscience Inc. dünya çapında ilaç keşif teknolojisi platformlarının araştırılması ve geliştirilmesiyle ilgilenmektedir.
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Chiome Bioscience Inc. Rakipler Fiyat Geçmişi ve Performans
için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Chiome Bioscience Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı JP¥107.00 52 Haftanın En Yüksek Seviyesi JP¥174.00 52 Haftanın En Düşük Seviyesi JP¥75.00 Beta 0.71 11 Aylık Değişim 7.00% 3 Aylık Değişim -4.46% 1 Yıllık Değişim -16.41% 33 Yıllık Değişim -55.60% 5 Yıllık Değişim -44.27% Halka arzdan bu yana değişim -63.57%
Son Haberler & Güncellemeler
Chiome Bioscience Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025 Nov 12
Second quarter 2024 earnings released: JP¥4.63 loss per share (vs JP¥9.00 loss in 2Q 2023) Aug 17
Chiome Bioscience Inc. to Report Q3, 2024 Results on Nov 12, 2024 Aug 14
Is Chiome Bioscience (TSE:4583) Using Too Much Debt? Jun 28
Chiome Bioscience Inc. to Report Q2, 2024 Results on Aug 13, 2024 Jun 13
Chiome Bioscience Inc. to Report Q1, 2024 Results on May 14, 2024 Mar 01 Daha fazla güncelleme görün
Chiome Bioscience Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025 Nov 12
Second quarter 2024 earnings released: JP¥4.63 loss per share (vs JP¥9.00 loss in 2Q 2023) Aug 17
Chiome Bioscience Inc. to Report Q3, 2024 Results on Nov 12, 2024 Aug 14
Is Chiome Bioscience (TSE:4583) Using Too Much Debt? Jun 28
Chiome Bioscience Inc. to Report Q2, 2024 Results on Aug 13, 2024 Jun 13
Chiome Bioscience Inc. to Report Q1, 2024 Results on May 14, 2024 Mar 01
Full year 2023 earnings released: JP¥24.13 loss per share (vs JP¥28.26 loss in FY 2022) Feb 14
Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2024 Feb 13
Chiome Bioscience Inc. to Report Fiscal Year 2023 Results on Feb 13, 2024 Dec 05
New minor risk - Share price stability Nov 22
Third quarter 2023 earnings released: JP¥5.25 loss per share (vs JP¥5.79 loss in 3Q 2022) Nov 15
Chiome Bioscience Inc. to Report Q3, 2023 Results on Nov 14, 2023 Aug 27 Chiome Bioscience Inc. announced that it expects to receive ¥13.49304 million in funding Jul 06
Chiome Bioscience Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jun 02
Full year 2022 earnings released: JP¥28.26 loss per share (vs JP¥36.74 loss in FY 2021) Feb 17
Chiome Bioscience Inc., Annual General Meeting, Mar 28, 2023 Feb 14
Chiome Bioscience Inc. to Report Fiscal Year 2022 Results on Feb 14, 2023 Dec 28
Third quarter 2022 earnings released: JP¥5.96 loss per share (vs JP¥10.77 loss in 3Q 2021) Nov 16
No independent directors Nov 16
Chiome Bioscience Inc. to Report Q3, 2022 Results on Nov 14, 2022 Sep 28
First half 2022 earnings released: JP¥18.17 loss per share (vs JP¥10.16 loss in 1H 2021) Aug 16
Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-1535 in A Phase 1 Clinical Trial Jul 05
Chiome Bioscience Inc. Announces Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study Jun 13
Chiome Bioscience Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jun 02
No independent directors Apr 27
Chiome Bioscience Inc. to Report Q1, 2022 Results on May 13, 2022 Apr 08
Chiome Bioscience Inc. Submits an Initial Application for Phase I Study on CBA-1535 Feb 17
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 16
Chiome Bioscience Inc., Annual General Meeting, Mar 25, 2022 Feb 15
Chiome Bioscience Inc. Announces Move to the Second Half Part of Phase 1 Clinical Trial of First-In-Class CBA-1205 Dec 24
Chiome Bioscience Inc. announced that it has received ¥16.8 million in funding from SMBC Nikko Securities Inc., Investment Arm Dec 16
Chiome Bioscience Inc. announced that it expects to receive ¥16.8 million in funding from SMBC Nikko Securities Inc., Investment Arm Nov 30
Second quarter 2021 earnings released: JP¥6.16 loss per share (vs JP¥9.25 loss in 2Q 2020) Aug 18
First quarter 2021 earnings released: JP¥4.07 loss per share (vs JP¥12.78 loss in 1Q 2020) May 16
Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2021 Feb 09
Chiome Bioscience Inc. to Report Fiscal Year 2020 Results on Feb 09, 2021 Jan 31
Shanghai Henlius Biotech, Inc. Enters into Exclusive License Agreement with Chiome Bioscience Inc. for Development and Commercialization of the Anti-Tpor-2 Antibodies, Liv-2008/2008B Jan 15
New 90-day high: JP¥241 Jan 15
New 90-day low: JP¥203 Dec 08
Chiome Bioscience Inc. Announces Amendment to the License Agreement with ADC Therapeutics Nov 11
Chiome Bioscience Inc. to Report Q3, 2020 Results on Nov 10, 2020 Aug 30
Chiome Bioscience Inc. to Report Q2, 2020 Results on Aug 11, 2020 Jun 28 Hissedar Getirileri 4583 JP Life Sciences JP Pazar 7D 7.0% 7.1% 3.2% 1Y -16.4% -18.8% 15.2%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 4583 geçen yıl % -18.8 oranında getiri sağlayan JP Life Sciences sektörünü aştı.
Getiri vs Piyasa: 4583 geçen yıl % 15.2 oranında getiri sağlayan JP Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 4583's price volatile compared to industry and market? 4583 volatility 4583 Average Weekly Movement 9.3% Life Sciences Industry Average Movement 6.5% Market Average Movement 4.0% 10% most volatile stocks in JP Market 7.7% 10% least volatile stocks in JP Market 2.2%
İstikrarlı Hisse Senedi Fiyatı: 4583 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: 4583 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala JP hisselerinin %75'inden yüksek.
Şirket Hakkında Chiome Bioscience Inc. dünya çapında ilaç keşif teknolojisi platformlarının araştırılması ve geliştirilmesiyle ilgilenmektedir. Şirket, İlaç Keşfi İşi ve İlaç Keşfi Destek İşi olmak üzere iki segmentte faaliyet göstermektedir. İlaç keşfi ve geliştirilmesi için monoklonal antikor üreten bir sistem olan ADLib Sistemi ve insanlaştırılmış antikorlara dönüştürülmüş bir tavuk antikor geni olan İnsan ADLib Sistemi sunmaktadır.
Daha fazla göster Chiome Bioscience Inc. Temel Bilgiler Özeti Chiome Bioscience'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 4583 temel i̇stati̇sti̇kler Piyasa değeri JP¥6.55b Kazançlar(TTM ) -JP¥1.12b Gelir(TTM ) JP¥587.30m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 4583 gelir tablosu (TTM ) Gelir JP¥587.30m Gelir Maliyeti JP¥262.63m Brüt Kâr JP¥324.68m Diğer Giderler JP¥1.44b Kazançlar -JP¥1.12b
Son Raporlanan Kazançlar
Jun 30, 2024
Sonraki Kazanç Tarihi
Feb 13, 2025
Hisse başına kazanç (EPS) -18.29 Brüt Marj 55.28% Net Kâr Marjı -190.76% Borç/Özkaynak Oranı 27.3%
4583 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
